Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Related Citations for PubMed (Select 24707943)

1.

Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.

Frankfurt O, Ma S, Gordon L, Winter JN, Horowitz JM, Rademaker A, Weitner BB, Peterson LC, Altman JK, Tallman MS, Petrich A, Rosen ST.

Leuk Lymphoma. 2015 Feb;56(2):315-23. doi: 10.3109/10428194.2014.910654. Epub 2014 Jun 17.

PMID:
24707943
2.

Alemtuzumab for patients with chronic lymphocytic leukaemia.

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD008078. doi: 10.1002/14651858.CD008078.pub2. Review.

PMID:
22336834
3.

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.

Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA.

J Clin Oncol. 2010 Oct 10;28(29):4500-6. doi: 10.1200/JCO.2010.29.7978. Epub 2010 Aug 9.

4.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
5.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

PMID:
23152253
7.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG.

Blood. 2011 Aug 25;118(8):2062-8. doi: 10.1182/blood-2011-01-329177. Epub 2011 Jul 12.

8.

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hillmen P.

J Clin Oncol. 2005 May 1;23(13):2971-9. Epub 2005 Feb 28.

9.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.

10.

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

Del Poeta G, Del Principe MI, Buccisano F, Maurillo L, Capelli G, Luciano F, Perrotti AP, Degan M, Venditti A, de Fabritiis P, Gattei V, Amadori S.

Cancer. 2008 Jan 1;112(1):119-28.

11.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group.

Blood. 2002 Nov 1;100(9):3115-20.

12.

[Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].

Li F, Yi SH, Yu Z, Xing LJ, Xu Y, Qi JY, Zhao YZ, Li ZJ, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2013 May;34(5):383-8. doi: 10.3760/cma.j.issn.0253-2727.2013.05.002. Chinese.

13.

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.

Blum KA, Young D, Broering S, Lucas MS, Fischer B, Lin TS, Grever MR, Byrd JC.

J Clin Oncol. 2007 Dec 10;25(35):5624-9. Epub 2007 Nov 5.

14.

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.

Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ.

Cancer. 2010 May 15;116(10):2360-5. doi: 10.1002/cncr.24958. Erratum in: Cancer. 2010 Aug 15;116(16):3982. Dosage error in article text.

15.

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE.

Cancer. 2008 Oct 15;113(8):2110-8. doi: 10.1002/cncr.23824.

16.

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network.

J Clin Oncol. 2003 May 1;21(9):1746-51.

PMID:
12721250
17.

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Zent CS, Wu W, Bowen DA, Hanson CA, Pettinger AM, Shanafelt TD, Kay NE, Leis JF, Call TG.

Leuk Lymphoma. 2013 Mar;54(3):476-82. doi: 10.3109/10428194.2012.717276. Epub 2012 Aug 22.

PMID:
22853816
18.

Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.

Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G.

Haematologica. 2004 Oct;89(10):1248-52.

19.

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST.

Leuk Lymphoma. 2004 Nov;45(11):2269-73.

PMID:
15512816
20.

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.

Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk